| Olutasidenib studied in …STUDIED_INderived14 of 14show fewer |
|---|
| → studied in | NCT05564390Phase 2 · recruiting MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) · 14 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06566742Phase 2 · recruiting A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. · 14 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06597734Phase 2 · withdrawn A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm · 14 trials list this drug (12 active) | — | — | Myeloproliferative Neoplasm,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06668584Phase 2 · recruiting A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies · 14 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07032727Phase 2 · recruiting Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations · 14 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07153497Phase 2 · not yet recruiting Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) · 14 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07471841Phase 2 · recruiting Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax · 14 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07411586Phase 1 · active not recruiting Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia · 14 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07486713Phase 4 · recruiting Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · 14 trials list this drug (12 active) | — | — | Glioma,Acute Myeloid Leukemia,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07304011Phase 2 · recruiting Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent · 14 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604064Phase 2 · recruiting A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia · 14 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06782542Phase 2 · recruiting Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy · 14 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06543381Phase 1 · recruiting Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant · 14 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03684811Phase 1/Phase 2 · completed A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation · 14 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |